The Shares of the Company are listed on the following Stock Exchanges: 

National Stock Exchange of India Limited

Exchange Plaza, Plot No. C/1 G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai - 400051 

NSE Symbol: BALAXI 

 

For Investor Grievances, Please Contact:

Mr. Mohith Kumar Khandelwal

(Company Secretary and Compliance Officer)

Balaxi Pharmaceuticals Limited

Plot No.409, H. No: 8-2-293,
MAPS Towers, 3rd Floor,
Phase-III, Road No: 81, Jubilee Hills,
Hyderabad, Telangana, India, 500 096

Phone: +91 40 2355-5300

Email: [email protected]

Registrars & Share Transfer Agent:

Aarthi Consultants Private Limited

1-2-285, Domalguda,
Hyderabad-500029

Ph: 040-27638111, 27634445
Fax: 040-27632184

Email: [email protected]

Nodal Officer (For Unclaimed Dividend/ Shares):

Name	Designation	Address and Contact Number	Email ID
Mr. Mohith Kumar Khandelwal	Company Secretary and Compliance Officer	Address: Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase - III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) – 500 096.   Contact Number: +91 40 23555300	[email protected]

 

Link for the Smart Online Dispute Resolution Portal is as follows: https://smartodr.in/login 

Attention Physical Security Holders: 

SEBI, vide its circular dated November 03, 2021 (subsequently amended by circulars dated December 14, 2021, March 16, 2023 and November 17, 2023) mandated that the security holders (holding securities in physical form), whose folio(s) do not have PAN or Choice of Nomination or Contact Details or Mobile Number or Bank Account Details or Specimen Signature updated, shall be eligible for any payment including dividend, interest or redemption in respect of such folios, only through electronic mode with effect from April 01, 2024.

Further, relevant FAQs have also been published by SEBI on its website at the following web link for investor awareness:

https://www.sebi.gov.in/sebi_data/faqfiles/jan-2024/1704433843359.pdf